Journal: ACS Omega

Article Title: Multimodal Mechanism of Antitumoral Ni(II) Thiosemicarbazones: Deep Mechanistic Understanding of ROS Dynamics, Albumin-Mediated Delivery, and DNA Targeting

doi: 10.1021/acsomega.5c12067

Figure Lengend Snippet: IC 50 Values at 24 and 48 h for HL60, A549, H2052, and HT29 Cancer Cell Lines and for the HuDe Healthy Cell Line

Article Snippet: Cell lines used for biological experiments were adenocarcinomic human alveolar basal epithelial cells A549, the human acute promyelocytic leukemia cell line HL60, the human colorectal adenocarcinoma cell line HT29, and the human epithelial mesothelioma cell line H2052 (ATCC, Rockville, Maryland, United States), using non-neoplastic human dermal fibroblast cell line HuDe (Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia (IZSLE), Brescia, Italy) for selectivity analysis.

Techniques:

Journal: Clinical Cancer Research

Article Title: Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique

doi: 10.1158/1078-0432.CCR-25-2694

Figure Lengend Snippet: In vitro validation of the Pep@MNP platform for specific capture and identification of thyroid cancer cells. A and B, Immunofluorescence staining of the capture marker EpCAM ( A ) and the identification marker CKmix ( B ) in thyroid cancer cell lines (BHT101 and BCPAP) and a negative control cell line (HL60). Nuclei were counterstained with DAPI. Scale bars, 10 μm. C, Quantitative analysis of the MFI of CKmix in BHT101, BCPAP, and HL60 cells, demonstrating significantly higher expression in thyroid cancer cells. D and E, FCM analysis confirming the surface expression of EpCAM ( D ) and high intracellular expression of CKmix ( E ) in BHT101 and BCPAP cells but not in HL60 cells. F, Scanning electron microscopy images showing the specific binding of Pep@MNPs to target BCPAP cells, whereas bare MNPs show minimal interaction. Both nanoparticle types show negligible binding to the negative control HL60 cells. Scale bars, 5 μm (top row) and 3 μm (bottom row). G, Representative immunofluorescence images defining the criteria for identifying a captured BCPAP cell (CTCs-like phenotype: DAPI+/CKmix+/CD45 − ) and distinguishing it from a co-captured white blood cell (WBC; DAPI+/CKmix − /CD45 + ). H, Capture sensitivity analysis. The graph shows the capture efficiency of the platform for varying numbers of BCPAP cells spiked into a solution. I, Capture specificity analysis. The graph compares the capture efficiency of the platform for cells with high EpCAM expression (BCPAP), low EpCAM expression (BHT101), and negative EpCAM expression (HL60). ****, P value < 0.0001.

Article Snippet: The human thyroid cancer cell lines BCPAP (RRID: CVCL_0153) and BHT101 (RRID: CVCL_1085), and the human promyelocytic leukemia cell line HL60 (RRID: CVCL_0002), were obtained from Procell Life Science & Technology in August 2021.

Techniques: In Vitro, Biomarker Discovery, Immunofluorescence, Staining, Marker, Negative Control, Expressing, Electron Microscopy, Binding Assay